0001399529-21-000116.txt : 20210615
0001399529-21-000116.hdr.sgml : 20210615
20210615191911
ACCESSION NUMBER: 0001399529-21-000116
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210611
FILED AS OF DATE: 20210615
DATE AS OF CHANGE: 20210615
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ciappenelli Robert D.
CENTRAL INDEX KEY: 0001778786
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36281
FILM NUMBER: 211020110
MAIL ADDRESS:
STREET 1: DICERNA PHARMACEUTICALS, INC.
STREET 2: 87 CAMBRIDGEPARK DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02140
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Dicerna Pharmaceuticals Inc
CENTRAL INDEX KEY: 0001399529
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 205993609
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 75 HAYDEN AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 617 621 8097
MAIL ADDRESS:
STREET 1: 75 HAYDEN AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
4
1
wf-form4_162379913307013.xml
FORM 4
X0306
4
2021-06-11
0
0001399529
Dicerna Pharmaceuticals Inc
DRNA
0001778786
Ciappenelli Robert D.
C/O DICERNA PHARMACEUTICALS, INC.
75 HAYDEN AVENUE
LEXINGTON
MA
02421
0
1
0
0
Chief Commercial Officer
Common Stock
2021-06-11
4
M
0
10000
15.61
A
13773
D
Common Stock
2021-06-11
4
S
0
10000
35
D
3773
D
Common Stock
2021-06-14
4
M
0
20000
15.61
A
23773
D
Common Stock
2021-06-14
4
S
0
20000
38
D
3773
D
Employee Stock Option (Right to Buy)
15.61
2021-06-11
4
M
0
10000
0
D
2029-06-30
Common Stock
10000.0
290000
D
Employee Stock Option (Right to Buy)
15.61
2021-06-14
4
M
0
20000
0
D
2029-06-30
Common Stock
20000.0
270000
D
The Reporting Person sold an aggregate of 10,000 shares of Common Stock on June 11, 2021 (the "Shares Sold No. 1") as reported in this Form 4. The Shares Sold No. 1 represent 2.08% of 481,298 shares of Common Stock, which is the number of shares of Common Stock owned by the Reporting Person prior to the Shares Sold No. 1 transaction reported in this Form 4, as well as shares issuable upon exercise or settlement of vested and unvested options and restricted stock units held by the Reporting Person as of the date of this report.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 10, 2020.
The Reporting Person sold an aggregate of 20,000 shares of Common Stock on June 14, 2021 (the "Shares Sold No. 2") as reported in this Form 4. The Shares Sold No. 2 represent 4.24% of 471,298 shares of Common Stock, which is the number of shares of Common Stock owned by the Reporting Person prior to the Shares Sold No. 2 transaction reported in this Form 4, as well as shares issuable upon exercise or settlement of vested and unvested options and restricted stock units held by the Reporting Person as of the date of this report.
The option vests 25% on the first year anniversary of the vesting start date of June 3, 2019 and the remaining 75% vests in 36 substantially equal monthly installments thereafter, subject in each case to the Reporting Person's continued employment or service with the Issuer through the applicable vesting date.
/s/ Douglas W. Pagan, attorney-in-fact
2021-06-15